NasdaqCM - Nasdaq Real Time Price • USD
Cingulate Inc. (CING)
As of 1:59 PM EDT. Market Open.
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Shane J. Schaffer Pharm.D., PharmD | CEO & Chairman of the Board | 491.96k | -- | 1975 |
| Dr. Laurie A. Myers M.B.A., Ph.D. | Executive VP & COO | 415.17k | -- | 1957 |
| Dr. Matthew N. Brams M.D. | Executive VP & Chief Medical Officer | 244.79k | -- | 1964 |
| Dr. Raul R. Silva M.D. | Executive VP & Chief Science Officer | -- | -- | 1958 |
| Thomas Dalton | Vice President of Investor & Public Relations | -- | -- | -- |
Cingulate Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 13
Description
Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
Corporate Governance
Cingulate Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Related Tickers
GRI GRI Bio, Inc.
0.3193
+0.41%
EPRX Eupraxia Pharmaceuticals Inc.
2.8249
-3.59%
CYTO Altamira Therapeutics Ltd.
1.7500
-1.69%
ATNF 180 Life Sciences Corp.
1.5616
-3.60%
TOVX Theriva Biologics, Inc.
0.2670
-12.75%
COEP Coeptis Therapeutics Holdings, Inc.
0.2792
-2.95%
GOVX GeoVax Labs, Inc.
1.6100
-7.47%
SILO Silo Pharma, Inc.
1.9400
-0.51%
DRMA Dermata Therapeutics, Inc.
3.3400
-2.34%
RENB Renovaro Inc.
1.6000
+12.68%